Richard LeBlanc
Overview
Explore the profile of Richard LeBlanc including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
2310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mian H, Visram A, Shih S, Trudel S, Hay A, LeBlanc R, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39952851
Measurable/minimal residual disease (MRD) is 1 of the most powerful prognostic factors for progression-free survival and overall survival in multiple myeloma (MM) and may guide therapeutic approaches. Here, we provide...
2.
LeBlanc R, Thiant S, Terra R, Ahmad I, Claveau J, Bambace N, et al.
Curr Oncol
. 2024 Nov;
31(11):7258-7274.
PMID: 39590165
Background: To date, the only potential curative treatment for multiple myeloma (MM) remains allogeneic (allo) hematopoietic cell transplant (HCT), although, most patients will eventually relapse. In relapsed patients, donor lymphocyte...
3.
Khan S, Bergstrom D, Cote J, Kotb R, LeBlanc R, Louzada M, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
25(3):e151-e172.
PMID: 39567294
The availability of effective therapies for multiple myeloma (MM) has sparked debate on the role of first line autologous stem cell transplantation (ASCT), particularly in standard-risk patients. However, treatment for...
4.
Terra R, Ethier V, Busque L, Morin-Quintal A, DAngelo G, Hebert J, et al.
Cytometry B Clin Cytom
. 2024 Nov;
PMID: 39538364
Rare acute leukemia (AL) components or subtypes such as blastic plasmacytoid dendritic cell neoplasm (BPDCN) or early T-cell precursor acute Lymphoblastic Leukemia (ETP-ALL) can be difficult to detect by routine...
5.
Tanguay M, Roy J, Su J, Gul E, Reece D, Venner C, et al.
Cancer Med
. 2024 Nov;
13(21):e70332.
PMID: 39499045
Background: Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature. Methods: We explored disease characteristics, treatments, and...
6.
Roy J, Cohen S, Sauvageau G, Ahmad I, Fournier V, Terra R, et al.
Transplant Cell Ther
. 2024 Oct;
31(1):34.e1-34.e14.
PMID: 39419177
Multiple myeloma (MM) remains associated with a poor outcome, particularly in patients with advanced disease and high-risk (HR) cytogenetics. To date, the only curative treatment is allogeneic (allo) hematopoietic cell...
7.
Tessier C, LeBlanc R, Roy J, Trudel S, Cote J, Lalancette M, et al.
Cancer Med
. 2024 Sep;
13(17):e70192.
PMID: 39225552
Background: Plasma cell leukemia (PCL) is a rare monoclonal gammopathy, associated with short survival. Because of its very low incidence, only a few cohorts have been reported and thus, information...
8.
Groh A, LeBlanc R
J Hist Neurosci
. 2024 Aug;
34(1):1-28.
PMID: 39163025
Wilder Penfield is known for his contributions to the structure-function relationship of the brain and for the surgical treatment of focal epilepsy. Less well known are his contributions to the...
9.
LeBlanc R
Front Psychol
. 2024 Aug;
15:1404953.
PMID: 39108437
This paper discusses a neglected aspect of the historiography of aphasia, the role that Pavlovian conditioning played in Alexander Luria's and Wilder Penfield's understanding of the acquisition, expression, and loss...
10.
Venner C, Duggan P, Song K, Reece D, Sharma S, Su J, et al.
Transplant Cell Ther
. 2024 Jul;
30(9):889-901.
PMID: 38971462
In patients with multiple myeloma (MM), the presence of high-risk cytogenetic abnormalities is associated with worse disease control and survival. Autologous stem cell transplant (ASCT) does benefit these patients. Tandem...